Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation

Abstract

Our PCR-guided and rituximab-based preemptive approach to avoid PTLD after allogeneic hematopoietic stem-cell transplantation is feasible but probably overtreated patients. Prospective trials are strongly needed, they should use uniform PCR techniques and consider higher threshold values for treatment initiation.